Citations

Clear

131 citation(s) found for "Me, Hay Me".

Percutaneous Ethanol Injection for Treatment of Cervical Lymph Node Metastases in Patients with Papillary Thyroid Carcinoma
Lewis, Bradley, Hay, Ian D. , Charboneau, J. William, McIver, Bryan, Reading, Carl C., Goellner, John R.

Mayo Clinic

American Journal of Roentgenology | February 28, 2013 | Volume: 178 | Issue: 3 | Pages: 699-704

10.2214/ajr.178.3.1780699 | PMID 11856701 Get It

Optimization of Peptide Hydroxamate Inhibitors of Insulin-Degrading Enzyme Reveals Marked Substrate-Selectivity
Abdul‐Hay, Samer O., Lane, Amy L. , Caulfield, Thomas R. , Claussin, Clémence , Bertrand, Juliette , Masson, Amandine, Choudhry, Shakeel, Fauq, Abdul H. , Maharvi, Guhlam M., Leissring, Malcolm A. , Caulfield, Thomas R , Lane, Amy L

Mayo Clinic

Journal of Medicinal Chemistry | February 25, 2013 | Volume: 56 | Issue: 6 | Pages: 2246-2255

10.1021/jm301280p | PMID 23437776 Get It

Receptor activity‐modifying protein‐dependent impairment of calcitonin receptor splice variant Δ(1–47)hCT(a)function
Qi, Tao, Dong, Maoqing , Watkins, HA, Wootten, Denise , Miller, L J, Hay, Debbie L. , Watkins, Harriet A.

Mayo Clinic

British Journal of Pharmacology | September 5, 2012 | Volume: 168 | Issue: 3 | Pages: 644-657

10.1111/j.1476-5381.2012.02197.x | PMID 22946511 Get It

Background and PurposeAlternative splicing expands proteome diversity toGPCRs. Distinct receptor variants have been identified for a secretin familyGPCR, the calcitonin receptor (CTR). The possible functional contributions of these receptor variants are further altered by their potential interactions with receptor activity‐modifying proteins (RAMPs). One variant of the humanCTRlacks the first 47 residues at itsNterminus [Δ(1–47)hCT(a)]. However, very little is known about the pharmacology of this variant or its ability to interact withRAMPsto form amylin receptors.Experimental ApproachΔ(1–47)hCT(a)was characterized both with and withoutRAMPsinCos7and/orHEK293Scells. The receptor expression (ELISAassays) and function (cAMPandpERK1/2 assays) for up to six agonists and two antagonists were determined.Key ResultsDespite lacking 47 residues at theNterminus, Δ(1–47)hCT(a)was still able to express at the cell surface, but displayed a generalized reduction in peptide potency. Δ(1–47)hCT(a)retained its ability to interact withRAMP1and formed a functional amylin receptor; this also appeared to be the case withRAMP3. On the other hand, its interaction withRAMP2and resultant amylin receptor was reduced to a greater extent.Conclusions and ImplicationsΔ(1–47)hCT(a)acts as a functional receptor at the cell surface. It exhibits altered receptor function, depending on whether it associates with aRAMPand whichRAMPit interacts with. Therefore, the presence of this variant in tissues will potentially contribute to altered peptide binding and signalling, depending on theRAMPdistribution in tissues.
Systemic and renal effects of nifedipine in cyclosporine-associated hypertension.
Textor, Stephen C., Schwartz, L , Wilson, Daniel J., Wiesner, Russell H., Romero, J. C. , Augustine, J., KOS, P., Hay, Eileen J., Dickson, E. Rolland, Gores, Gregory J.

Mayo Clinic

Hypertension | August 1, 2012 | Volume: 23 | Issue: 1_supplement | Pages: No page available

10.1161/01.hyp.23.1_suppl.i220 | PMID 8282363 Get It

Cyclosporine induces hypertension and wide-spread vasoconstriction after transplantation in addition to reducing kidney function. We studied hemodynamic, renal, and hormonal effects of monotherapy with nifedipine XL (n = 37) in liver transplant recipients within a year after transplant (median, 4.4 months). Systemic hemodynamics were determined with thoracic electrical bioimpedance. Blood pressure before therapy was 172 +/- 4/108 +/- 2 mm Hg. Sixty-four percent of recipients achieved blood pressures less than 140/90 mm Hg mediated by a fall in systemic vascular resistance index (2427 +/- 245 dyne.s.cm-5.m-2 in responders versus 2905 +/- 281 in nonresponders, P < .01). Despite the fall in systemic vascular resistance, glomerular filtration rates were not changed during nifedipine therapy, as measured by both creatinine and iothalamate clearances. Urinary prostacyclin (6-ketoprostaglandin F1 alpha) was suppressed below normal from 2468 +/- 323 ng/d before transplant to 1103 +/- 99 ng/d (P < .01) after transplant and did not change during nifedipine therapy. Urinary thromboxane B2 and plasma renin activity also fell after transplant and remained low during nifedipine. These data demonstrate that nifedipine can reverse systemic vasoconstriction associated with hypertension after transplantation. Systemic effects were not transmitted to the kidney sufficiently to improve glomerular filtration rate or reverse hormonal changes within the kidney. Hence, vascular and functional regulation of the kidney was dissociated from the systemic circulation during nifedipine administration after transplantation.
Thyroid Disorders, Noncommunicable Diseases That Gravely Impact Public Health: A Commentary and Statement by the Advisory Board of the World Thyroid Federation
Duntas, Leonidas H. , Amino, Nobuyuki, Peeters, Robin P. , Vaismann, Mario, Ward, Laura Sterian , Williams, Graham R. , Luis, Teofilo O.L. San, Yen, Paul M. , Hay, Ian , McDermott, Michael

Mayo Clinic

Thyroid | June 5, 2012 | Volume: 22 | Issue: 6 | Pages: 566-567

10.1089/thy.2012.0153 | PMID 22667451 Get It

Development of a Multidisciplinary, Multicampus Subspecialty Practice in Endocrine Cancers
Bible, Keith C. , Smallridge, Robert C., Morris, John C., Molina, Julian R. , Copland, John A. , Rubin, Joseph, Menefee, Michael E., Sideras, Kostandinos , Maples, William J., McIver, Bryan, Fatourechi, Vahab , Foote, Robert L. , Garces, Yolanda I. , Kasperbauer, Jan L. , Thompson, Geoffrey B. , Grant, Clive S., Richards, Melanie L. , Sebo, Thomas J., Lloyd, Ricardo V., Eberhardt, Norman L., Casler, John D., Karlin, Nina J. , Westphal, Sydney A., Richardson, Ronald L., Buckner, Jan C. , Erlichman, Charles , Suman, Vera J. , Hay, Ian , Reddi, Honey V. , Sideras, Kostandinos

Mayo Clinic

Journal of Oncology Practice | May 20, 2012 | Volume: 8 | Issue: 3S | Pages: e1s-e5s

10.1200/jop.2011.000496 | PMID 22942830 Get It

The development of subspecialty tumor groups for uncommon malignancies represents an effective approach to building experience, increasing patient volumes and referrals, and fostering development of increased therapeutic options and clinical trials for patients afflicted with otherwise historically neglected cancers.
The association between Alzheimer's disease and thyroid disease in Rochester, Minnesota
Yoshimasu, F, Kokmen, E., Beard, C. Mary, Offord, K. P., Kurland, L. T., Hay, Ian

Mayo Clinic

Neurology | May 13, 2012 | Volume: 41 | Issue: 11 | Pages: 1745-1745

10.1212/wnl.41.11.1745 | PMID 1944903 Get It

O1‐05‐06: Functional cDNA screening identifies BACE‐2 as a principal beta‐amyloid degrading protease
Abdul‐Hay, Samer O., Sahara, Tomoko, McBride, Melinda, Kang, Dongcheul, Leissring, Malcolm A.

Mayo Clinic

Alzheimer's & Dementia | August 1, 2011 | Volume: 7 | Issue: 4S_Part_3 | Pages: No page available

10.1016/j.jalz.2011.05.261 Get It

Invasive Fibrous Thyroiditis (Riedel Thyroiditis): The Mayo Clinic Experience, 1976–2008
Fatourechi, Mitra M., McIver, Bryan, Sebo, Thomas J., Fatourechi, Vahab , Hay, Ian

Mayo Clinic

Thyroid® | May 13, 2011 | Volume: 21 | Issue: 7 | Pages: 765-772

10.1089/thy.2010.0453 | PMID 21568724 Get It

Background: Invasive fibrous thyroiditis (IFT) is the rarest form of thyroiditis, and reports are often limited to case reports and small case series. In this study, we aimed to summarize our institutional experience with IFT since 1976. Methods: We retrospectively reviewed the cases of all patients with IFT evaluated at Mayo Clinic, Rochester, Minnesota, from 1976 through 2008, with special emphasis on clinical presentation, associated risk factors, associated comorbid conditions, complications, and treatment. Results: Twenty-one patients met our inclusion criteria of (i) IFT confirmed by pathologic review at our institution and (ii) evidence of extension of fibrosis outside the thyroid capsule. Most patients (17, 81%) were women (mean age, 42 years). Presenting symptoms included pain (24%), dysphagia (33%), vocal cord paralysis (29%), and tracheal narrowing (48%). Three patients had associated hypoparathyroidism. Sixteen (76%) had a history of tobacco use, and 10 (48%) were current smokers. Fibrosing mediastinitis was present in four, orbital fibrosis in one, retroperitoneal fibrosis in three, and pancreatic fibrosis in one (38% had extracervical fibrotic processes). Eighteen patients had partial thyroidectomy, 7 (39%) of whom had surgical complications involving vocal cords and parathyroid. Two required tracheostomy. Thirteen had corticosteroid therapy; six received tamoxifen. There was no cause-specific mortality, and the fibrotic process stabilized or partially resolved in all patients. Conclusions: IFT often is associated with a systemic extracervical fibrotic process and tobacco use. Attempted thyroid resection often results in postoperative complications. Long-term follow-up showed no deaths from IFT and showed stability of the thyroiditis.